Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Veracyte (VCYT)

Veracyte completes $150 million cash acquisition of Convergent Genomics

Neutral Impact 5 of 5 m&a Written later

Veracyte, Inc. completed its acquisition of Convergent Genomics on September 14, 2026, through a merger under an agreement signed September 10, 2026, adding the UroAmp urine tumor DNA platform for bladder cancer. The filing states the company did not update its previously provided 2026 adjusted EBITDA guidance, which already contemplated Convergent's operating expenses, and no financial results for Convergent were disclosed.

Key points

  • Upfront cash consideration of $150 million, subject to customary purchase price adjustments
  • Up to $30 million in additional cash tied to UroAmp publication and reimbursement milestones
  • Merger agreement dated September 10, 2026; closing completed September 14, 2026
  • Veracyte expects to commercialize its first UroAmp-based test in late 2028, subject to reimbursement timelines

The filing

CompanyVeracyte (VCYT)
Form8-K, current report
Filed with the SECSep 14, 2026, 4:07 PM ET
Accession number0001384101-26-000049

Items reported: 1.01 Material Definitive Agreement2.01 Acquisition or Disposition Completed7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:55 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.